2023 World Conference on Lung Cancer (Posters)-P2.31. Clinical Outcomes of Real-World Treatment for Metastatic EGFRm NSCLC after Osimertinib and Platinum-Based Chemotherapy

P2.31. Clinical Outcomes of Real-World Treatment for Metastatic EGFRm NSCLC after Osimertinib and Platinum-Based Chemotherapy - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to investigate the clinical outcomes of real-world treatment in patients with metastatic EGFRm NSCLC after receiving osimertinib and platinum-based chemotherapy (PBC). The researchers used a database comprising de-identified patient data from approximately 280 US cancer clinics. The study included patients who met specific criteria, including a diagnosis of mNSCLC with an activating EGFR mutation, initiation of a new line of therapy after osimertinib and PBC, and no prior treatment with certain therapies. Propensity score weighting was used to ensure a similar distribution of baseline characteristics to a multinational phase II trial. The endpoints of the study were real-world overall survival (rwOS), real-world progression-free survival (rwPFS), and real-world confirmed objective response rate (confirmed rwORR).<br /><br />The results of the study showed that among the 126 eligible patients, the mean age was 65.8 years, and the majority were female, Caucasian, and non-smokers. After propensity score weighting, the median rwOS was 9.1 months, and the median rwPFS was 4.2 months. The confirmed rwORR was estimated to be 14.1%. These findings suggest that current therapies provide limited clinical benefit for patients with EGFRm NSCLC after osimertinib and PBC, highlighting a significant unmet need in this patient population. The researchers also emphasized that these data provide important context for interpreting the results of a study evaluating the safety and efficacy of patritumab deruxtecan in this patient population.<br /><br />In summary, this study demonstrates that patients with metastatic EGFRm NSCLC who receive osimertinib and platinum-based chemotherapy have limited clinical outcomes. These findings underscore the need for further treatment options for this patient population. The results of this study also provide important context for the evaluation of new therapies in this setting.

Asset Subtitle

Jyoti Patel

Meta Tag

Speaker Jyoti Patel

Topic Global Health, Health Services & Health Economics: Real World Data

Keywords

clinical outcomes

metastatic EGFRm NSCLC

osimertinib

platinum-based chemotherapy

real-world treatment

mNSCLC

propensity score weighting

overall survival

progression-free survival

objective response rate